Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Zacks Investment Research on MSN
OTLK stock crashes 67% in a week: Here's what you need to know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third ...
News-Medical.Net on MSN
Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...
A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit the Mcl-1 protein—an essential survival factor for therapy-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback